QuidelOrtho Corp (QDEL): Total Assets

Annual figures by period end, from SEC filings.

$5.77B
As of 2025-12-28
$5.72B
As of 2026-06-28
-13.3%
3-year compound annual growth
$8.86B2022-01-02: $2.43B2023-01-01: $8.86B2023-12-31: $8.56B2024-12-29: $6.42B2025-12-28: $5.77B$5.77B
2022-01-02 Total Assets (USD) 2025-12-28
Period endedTotal AssetsChange YoYSource filing
2025-12-28$5.77B-10.2%2026-02-19, Balance as of period end
2024-12-29$6.42B-25.0%2026-02-19, Balance as of period end
2023-12-31$8.56B-3.3%2025-02-27, Balance as of period end
2023-01-01, Fiscal 2022$8.86B+264.4%2024-08-01, Balance as of period end
2022-01-02, Fiscal 2021$2.43Bn/a2023-02-23, Balance as of period end

Total Assets at similar companies

Companies with the same SEC industry code (In Vitro & In Vivo Diagnostic Substances), reporting in the same currency, closest in revenue. Each shows its own latest fiscal year, so period ends differ.

CompanyYear endedTotal AssetsChange YoY
QuidelOrtho Corp (QDEL)2025-12-28$5.77B-10.2%
Idexx Laboratories Inc (IDXX)2025-12-31$3.35B+1.7%
Lantheus Holdings, Inc. (LNTH)2025-12-31$2.23B+12.5%
Neogen Corp (NEOG)2026-05-31$3.35B-2.8%
Myriad Genetics Inc (MYGN)2025-12-31$706.60M-31.2%
Intellia Therapeutics, Inc. (NTLA)2025-12-31$842.13M-29.3%
Alpha Teknova, Inc. (TKNO)2025-12-31$103.58M-12.8%
Immucell Corp (ICCC)2025-12-31$42.53M-5.7%
Aspira Women's Health Inc. (AWHL)2025-12-31$5.46M-0.6%

Compare QDEL, IDXX, LNTH, NEOG side by side · Screen every company in In Vitro & In Vivo Diagnostic Substances ↗